Takeda Pharmaceutical (TAK) Other Working Capital Changes (2022 - 2025)

Takeda Pharmaceutical has reported Other Working Capital Changes for 9 years, with the latest figure at -$70.7 million in Q2 2026.

• On a quarterly basis, Other Working Capital Changes rose 16.23% year-over-year to -$70.7 million in Q2 2026; TTM through Jun 2026 was -$295.6 million, a 4.95% increase from a year earlier, with the FY2026 full-year figure at -$272.7 million, up 8.03% from the prior year.
• Other Working Capital Changes was -$70.7 million for Q2 2026 at Takeda Pharmaceutical, down from -$68.6 million in the prior quarter.
• The five-year high for Other Working Capital Changes was -$627.8 million in Q3 2025, with the low at -$1.2 billion in Q3 2022.
• Average Other Working Capital Changes over 3 years is -$1.1 billion, with a median of -$1.2 billion recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Other Working Capital Changes sank 80.8% in 2023, then soared 51.71% in 2024.
• Over 5 years, Other Working Capital Changes stood at -$81.5 million in 2022, then tumbled by 80.8% to -$147.4 million in 2023, then jumped by 51.71% to -$71.2 million in 2024, then advanced by 3.55% to -$68.6 million in 2025, then retreated by 2.95% to -$70.7 million in 2026.
• The last three Other Working Capital Changes figures came in at -$70.7 million (Q2 2026), -$68.6 million (Q3 2025), and -$84.4 million (Q2 2025), per Business Quant data.